As head of lifecycle and pipeline at AstraZeneca, Benjamin leads a large senior division responsible for several core global remits covering clinical trial and portfolio investment decisions for oncology assets and delivers all asset and above-asset tumour-level strategy work streams and pan-portfolio prioritisation setting. This includes new opportunity ideation and development, asset valuations, market and opportunity assessments, market research, competitor analysis, asset profiling, trial design, emerging standards of care evaluation and mapping. The department also supports all in-licensing, search & evaluation, co-development and business development deals and leads advisory boards and medical congress strategy coverage.
Benjamin is a core member of several AZ leadership and governance committees including the Early Stage Product Committee, the Oncology Research Board Committee and the Forecast Review Committee.
In 2021, Benjamin also joined The Department of Cancer and Surgery at Imperial College as a Senior Honorary Research Fellow where he provides a series of lectures covering oncology strategy, clinical trial design, forecasting and drug commercialisation as part of the MRes Cancer Biology course
Benjamin holds a First Class Honours degree in Biochemistry from Imperial College and a PhD from University College London.
The talk will include an overview of oncology market dynamics and sizing, principles of forecasting, asset (drug) valuation and commercialisation considerations.